Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

Wadhera, Rishi K.; Rajkumar, S. Vincent
October 2010
Mayo Clinic Proceedings;Oct2010, Vol. 85 Issue 10, p933
Academic Journal
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant piasma ceii disorder that is associated with a life-long risk of multiple myeioma. We conducted a systematic review of all studies investigating the prevalence and Incidence of MGUS in the online database PubMed. The review was conducted from January 6, 2009, through January 15, 2010. The following MeSH search headings were used: monoclonal gammopathy, benign and prevalence; monoclonal gammopathy, benign and incidence; para- protelnemia and prevalence; and paraprotelnemia and Incidence. Articles were limited to those written in English and published by January 2009. Fourteen studies that met prespecifled criteria were included and systematically assessed to identify the most accurate prevalence estimates of MGUS based on age, sex, and race. On the basis of our systematic review, we estimate that the crude prevalence of MGUS in those older than 50 years is 3.2% in a predominantly white population. Studies In white and Japanese populations demonstrate a ciear Increase in prevalence with age. The prevalence Is also affected by sex: 3.7% and 2.9% In white men and women, respectively; and 2.8% and 1.6% In Japanese, men and women, respectively. Additionally, MGUS is significantly more prevalent in black people (5.9%-8.4%) than in white people (3.0%-3.6%). We conclude that MGUS is a common premalignant plasma cell disorder in the general population of those older than 50 years. The prevalence increases with age and is affected by race, sex, family history, immunosuppression, and pesticide exposure. These results are important for counseling, clinical care, and the design of clinical studies in high-risk populations.


Related Articles

  • Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Woitge, H W; Pecherstorfer, M; Horn, E; Keck, A-V; Diel, I J; Bayer, P; Ludwig, H; Ziegler, R; Seibel, M J // British Journal of Cancer;2/1/2001, Vol. 84 Issue 3, p344 

    To test the potential of immunoreactive BSP, a non-collagenous bone matrix component, as a clinical guide in patients with plasma cell dyscrasias, serum BSP concentrations were measured in 62 patients with newly diagnosed multiple myeloma (MM) followed over a period of 4 years, in 46 patients...

  • Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays. Katzmann, Jerry A.; Dispenzieri, Angela; Kyle, Robert A.; Snyder, Melissa R.; Plevak, Matthew F.; Larson, Dirk R.; Abraham, Roshini S.; Lust, John A.; Melton III, L. Joseph; Rajkumar, S. Vincent // Mayo Clinic Proceedings;Dec2006, Vol. 81 Issue 12, p1575 

    OBJECTIVE: To determine the relative diagnostic contribution of urine assays as part of the screening algorithm for monoclonal gammopathies. PATIENTS AND METHODS: We Identified 428 patients with a monoclonal gammopathy and monoclonal urinary protein at initial diagnosis of plasma cell dyscrasia...

  • Protein Electrophoresis and Immunofixation for the Diagnosis of Monoclonal Gammopathies. Rajkumar, S. Vincent; Kyle, Robert A. // JAMA: Journal of the American Medical Association;11/26/2014, Vol. 312 Issue 20, p2160 

    The article reviews the application of urine protein electrophoresis and serum immunofixation in the case of a woman in her 70s who was diagnosed with monoclonal gammopathy of undetermined significance (MGUS). Data provided shows the patient's laboratory values and describes the characteristics...

  • Serial exome analysis of disease progression in premalignant gammopathies. Zhao, S; Choi, M; Heuck, C; Mane, S; Barlogie, B; Lifton, R P; Dhodapkar, M V // Leukemia (08876924);Jul2014, Vol. 28 Issue 7, p1548 

    The article discusses the study on the serial exome analysis of disease progression in premalignant gammopathies. It notes the multiple myeloma (MM) characterized by progressive growth of malignant plasma cells where nearly all cases are preceded by asymptomatic monoclonal gammopathies (AMGs)....

  • Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study. Onwah, A. Lawretta; Adeyemo, Titilope A.; Adediran, Adewumi; Ajibola, Sarah O.; Akanmu, Alani S. // BMC Blood Disorders;2012, Vol. 12 Issue 1, p7 

    Background: The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premalignant plasma-cell disorder has not been determined in our geographic area Nigeria. Methods: A cross sectional survey was carried on apparently healthy Nigerians selected by multistage sampling...

  • Auer rod-like inclusions in plasma cells in multiple myeloma. Wai Khoon Ho; Daniela Zantomio // Journal of Clinical Pathology;Jun2014, Vol. 67 Issue 6, p547 

    The article presents a case study of a female patient who presented to physicians with bone pain. A discussion of diagnostic testing which was conducted on the patient, and resulted in her receiving a diagnosis of multiple myeloma with Auer rod-like inclusions in her plasma cells, is presented.

  • Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells. Fei ZHAO; Yan CHEN; Ling-lan ZENG; Rui LI; Rong ZENG; Lu WEN; Yuan LIU; Chun ZHANG // Acta Pharmacologica Sinica;Jun2010, Vol. 31 Issue 6, p733 

    AbstractAim:To investigate the effects of triptolide on proliferation and apoptosis as well as on the expression of RIZ1 in the human multiple myeloma cell line U266 in vitro.Methods:The effect of triptolide on the growth of U266 cells was studied by MTT assay. Apoptosis was detected by Hoechst...

  • A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. Kyle, Robert A.; Therneau, Terry M.; Rajkumar, S. Vincent; Offord, Janice R.; Larson, Dirk R.; Plevak, Matthew F.; Melton, L. Joseph // New England Journal of Medicine;2/21/2002, Vol. 346 Issue 8, p564 

    Background: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. Methods: We identified 1384 patients residing in...

  • Monoclonal Gammopathy of Undetermined Significance. Bladé, Joan // New England Journal of Medicine;12/28/2006, Vol. 355 Issue 26, p2765 

    The article discusses the diagnosis, evaluation, and treatment of a patient with the clinical problem monoclonal gammopathy of undetermined significance (MGUS). An overview of MGUS is presented along with various statistical information related to its prevalence and progression. The author...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics